◎ Sugi Atlas

Atlas / Gene / ADAMTS7

ADAMTS7

gene
On this page

Also known as ADAM-TS7DKFZp434H204

Summary

ADAMTS7 (ADAM metallopeptidase with thrombospondin type 1 motif 7, HGNC:223) is a protein-coding gene on chromosome 15q25.1, encoding A disintegrin and metalloproteinase with thrombospondin motifs 7 (Q9UKP4). Metalloprotease.

The protein encoded by this gene is a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Members of this family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The encoded preproprotein is proteolytically processed to generate the mature enzyme. This enzyme contains two C-terminal TS motifs and may regulate vascular smooth muscle cell (VSMC) migration. Mutations in this gene may be associated with susceptibility to coronary artery disease.

Source: NCBI Gene 11173 — RefSeq curated summary.

At a glance

  • GWAS associations: 83
  • Clinical variants (ClinVar): 402 total
  • Druggable target: yes
  • MANE Select transcript: NM_014272

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:223
Approved symbolADAMTS7
NameADAM metallopeptidase with thrombospondin type 1 motif 7
Location15q25.1
Locus typegene with protein product
StatusApproved
AliasesADAM-TS7, DKFZp434H204
Ensembl geneENSG00000136378
Ensembl biotypeprotein_coding
OMIM605009
Entrez11173

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000388820, ENST00000565793, ENST00000566303, ENST00000568712, ENST00000569934, ENST00000917170, ENST00000917171, ENST00000917172, ENST00000972106, ENST00000972107, ENST00000972108

RefSeq mRNA: 1 — MANE Select: NM_014272 NM_014272

CCDS: CCDS32303

Canonical transcript exons

ENST00000388820 — 24 exons

ExonStartEnd
ENSE000009428097877158578771829
ENSE000011613757881112178811464
ENSE000012073587876737978767592
ENSE000012074457877116278771303
ENSE000015935737875920678759578
ENSE000016033117876369978763845
ENSE000016479217876564578767051
ENSE000016927027876392678764099
ENSE000017256527876240378762565
ENSE000017531067876455578764707
ENSE000035065827877674978776841
ENSE000035119657877416778774300
ENSE000035215267879114078791223
ENSE000035351977877618878776333
ENSE000035428827879067078790794
ENSE000035569997878968978789838
ENSE000035708077878823178788374
ENSE000035959907879794878798113
ENSE000036034577877462478774793
ENSE000036448177879659078796786
ENSE000036889077880019278800547
ENSE000036923897877308378773203
ENSE000036924727877744478777588
ENSE000036937047876813378768259

Expression profiles

Bgee: expression breadth ubiquitous, 151 present calls, max score 92.69.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.5979 / max 176.7369, expressed in 1168 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter IDTPM avgSamples expressed
1511295.54811129
1511280.5390251
1511270.3791201
1511300.131630

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
right atrium auricular regionUBERON:000663192.69gold quality
cardiac atriumUBERON:000208191.36gold quality
apex of heartUBERON:000209889.32gold quality
stromal cell of endometriumCL:000225586.98gold quality
ganglionic eminenceUBERON:000402386.88gold quality
right coronary arteryUBERON:000162586.11gold quality
ascending aortaUBERON:000149684.06gold quality
thoracic aortaUBERON:000151583.66gold quality
heartUBERON:000094882.06gold quality
heart left ventricleUBERON:000208482.06gold quality
left coronary arteryUBERON:000162681.95gold quality
cardiac ventricleUBERON:000208280.95gold quality
coronary arteryUBERON:000162180.03gold quality
aortaUBERON:000094779.73gold quality
primordial germ cell in gonadCL:0000670 ∩ UBERON:000099179.59gold quality
descending thoracic aortaUBERON:000234578.58gold quality
cortical plateUBERON:000534378.14gold quality
sural nerveUBERON:001548877.99gold quality
right adrenal glandUBERON:000123377.56gold quality
left adrenal gland cortexUBERON:003582577.53gold quality
tibial nerveUBERON:000132377.19gold quality
popliteal arteryUBERON:000225077.15gold quality
tibial arteryUBERON:000761077.12gold quality
left adrenal glandUBERON:000123477.09gold quality
upper lobe of left lungUBERON:000895277.07gold quality
right ovaryUBERON:000211877.00gold quality
right adrenal gland cortexUBERON:003582776.16gold quality
body of uterusUBERON:000985376.12gold quality
omental fat padUBERON:001041476.05gold quality
peritoneumUBERON:000235875.98gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

ExperimentMarker?Max mean expression
E-ANND-3yes5.64

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HR, HTATIP2, SSRP1, TFAP2A, ZBTB16

miRNA regulators (miRDB)

24 targeting ADAMTS7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNAMax scoreAvg scoremiRNA target_count
HSA-MIR-29A-3P100.0073.111835
HSA-MIR-29B-3P100.0073.181833
HSA-MIR-29C-3P100.0073.151833
HSA-MIR-3924100.0072.092394
HSA-MIR-767-5P99.9570.85993
HSA-MIR-6753-3P99.9366.57637
HSA-MIR-7107-3P99.9366.73627
HSA-MIR-568299.8972.561005
HSA-MIR-7162-3P99.8968.161682
HSA-MIR-380-3P99.8970.181978
HSA-MIR-449599.8272.083080
HSA-MIR-472999.6972.184233
HSA-MIR-379-3P99.6969.601524
HSA-MIR-411-3P99.6969.631524
HSA-MIR-548G-3P99.4868.672159
HSA-MIR-6871-3P99.4368.85741
HSA-MIR-5589-5P98.3464.821148
HSA-MIR-6782-3P97.6067.75931
HSA-MIR-585-5P97.5469.02955
HSA-MIR-59697.4863.13469
HSA-MIR-6849-3P97.2564.571371
HSA-MIR-541-3P96.0766.111271
HSA-MIR-654-5P96.0766.181280
HSA-MIR-6734-5P95.7065.56950

Literature-anchored findings (GeneRIF, showing 40)

  • ADAMTS-7 is the first metalloproteinase found to bind directly to and degrade COMP (PMID:16585064)
  • ADAMTS-7 and ADAMTS-12 are newly identified enzymes responsible for cartilage oligomeric matrix protein degradation in arthritis. (PMID:19098927)
  • Findings demonstrate that ADAMTS-7, a direct target of PTHrP signaling, negatively regulates endochondral bone formation by associating with and inactivating GEP chondrogenic growth factor. (PMID:19487464)
  • identified ADAMTS7 as novel locus for CAD and association of ABO with MI in the presence of CAD (PMID:21239051)
  • statistically significant increase in mRNA expression of ADAMTS-7 and ADAMTS-12 was observed in the endplate cells in degenerative discs compared with nondegenerative discs (PMID:22247065)
  • There was a reduction in the amount of cleaved ADAMTS7 prodomain in media conditioned by VSMCs of the G/G genotype. (PMID:23415669)
  • Data conclude that ADAMTS-7 level appears to be positively associated with expression of TNF-alpha and Phospho-NF-kappaB P65 in cartilage, which may imply its association with cartilage destruction of ONFH. (PMID:25653475)
  • ADAMTS7 localized to cells having smooth muscle cell markers in human coronary artery disease lesions. Cultured vascular smooth muscle cells had ADAMTS7 at the cytoplasm and cell membrane, where it colocalized with markers of podosomes. (PMID:25712206)
  • Logistic regression analysis indicated that the association between ADAMTS-7 and heart failure after AMI was independent from traditional cardiovascular risk factors and other biomarkers (PMID:25885961)
  • The significant associations observed between this coding variant in ADAMTS7 and the risk of CAD development. (PMID:26189211)
  • Our results indicate the presence of ADAMTS-7 in human NP cells and imply its potential role in disc degeneration. (PMID:26446668)
  • miR-105/Runx2 axis mediates FGF2-induced ADAMTS expression in osteoarthritis cartilage. (PMID:26816250)
  • The main contribution of this study is the proposal of a pharmacophore for ADAMTS7. (PMID:26872430)
  • Expression of miR-26a and miR-29a was significantly down regulated in leukoplakia and cancer tissues but up regulated in lichen planus tissues. Expression of target genes such as, ADAMTS7, ATP1B1, COL4A2, CPEB3, CDK6, DNMT3a and PI3KR1 was significantly down regulated in at least two of three disease types with respect to normal tissues. (PMID:27515006)
  • During inflammatory conditions, AP-1 and Sp1 sustained the expression of ADAMTS7, and ADAMTS7 sustained the expression of catabolic genes in nucleus pulposus cells (PMID:27516213)
  • The native overfunctional ADAMTS7 allele (A) may accelerate VSMC migration and lead to neointimal thickening, atherosclerosis progression and acute plaque events. (PMID:27614204)
  • ADAMTS7 and LPA single nucleotide polymorphisms are related to a 24-h ambulatory systolic-diastolic pressure regression index. (PMID:28092973)
  • Studied gene expression of genetic variants of ADAMTS7 in atherosclerotic occlusive peripheral arterial disease (PAD). Found mRNA levels of ADAMTS7 to be significantly higher in PAD patients than controls, and that the rs1994016 CC and rs3825807 TT genotypes may upregulate ADAMTS7 mRNA levels and may influence PAD development. (PMID:28205274)
  • Allelic variation that associates with reduced ADAMTS7 expression confers stronger coronary heart disease protection in never-smokers than in ever-smokers. (PMID:28461624)
  • data show that ADAMTS-7 is associated with a vulnerable plaque phenotype in human carotid lesions. These data support previous observations of a potential proatherogenic role of ADAMTS-7. (PMID:28623250)
  • The findings suggest that upregulation of ADAMTS-7 and down regulation of COMP are associated with human AA. (PMID:28849199)
  • Genetic variation at the ADAMTS7 locus is associated with reduced severity of coronary artery disease. (PMID:29089340)
  • Multivariate analysis showed that DeltaADAMTS-7(day 7 minus day 1) was independently associated with left ventricular reverse remodeling (PMID:29523183)
  • Degenerated human biceps tendons had reduced ADAMTS7 mRNA compared with healthy biceps tendons, which expressed both ADAMTS7 and ADAMTS12. These results suggest that ADAMTS7 and ADAMTS12 may be essential for human tendon health. (PMID:29618652)
  • Serum ADAMTS7 level is positively associated with acute coronary syndrome, and patients with the CT/TT genotype at the rs1994016 allele are less prone to suffer from ACS. (PMID:29980058)
  • presents the expression levels of ADAMTS-7 and COMP in the decidual tissues of mice and humans suffering from SA. (PMID:30720083)
  • findings reveal LTBP4 as an ADAMTS7 substrate, whose cleavage may potentially impact elastogenesis in the cardiovascular system. (PMID:30926607)
  • ADAMTS7 tagSNP rs3825807 contributes to MI susceptibility in the Chinese Han population. (PMID:31292280)
  • Genetic variants of ADAMTS7 confer risk for ischaemic stroke in the Chinese population. (PMID:31460868)
  • ADAMTS7 polymorphisms of both rs7173743 and rs3825807 were associated with carotid plaque vulnerability but not the prevalence of ischemic stroke. The T/T genotype of rs7173743 and A/A genotype of rs3825807 were considered as risk genotypes for vulnerable plaque susceptibility. In conclusion, ADAMTS7 variants rs3825807 and rs7173743 are associated with the risk for carotid plaque vulnerability. (PMID:31651847)
  • Data show that common variants in A disintegrin and metalloproteinase with thrombospondin motifs 7 protein (ADAMTS7) and zinc finger, C3HC-type containing 1 protein (ZC3HC1) genes contribute to an increased risk for both coronary artery disease (CAD) and large artery ischemic stroke (LA atherosclerotic) IS. (PMID:31679296)
  • Upregulation of miR423 improves autologous vein graft restenosis via targeting ADAMTS7. (PMID:31894258)
  • Effect of a coronary-heart-disease-associated variant of ADAMTS7 on endothelial cell angiogenesis. (PMID:32005000)
  • ADATMS-7 regulates the focal adhesion kinase signaling and promotes invasiveness of trophoblasts in early pregnancy. (PMID:32148246)
  • Hypomethylation of DNA promoter upregulates ADAMTS7 and contributes to HTR-8/SVneo and JEG-3 cells abnormalities in pre-eclampsia. (PMID:32250736)
  • ADAMTS7 degrades Comp to fuel BMP2-dependent osteogenic differentiation and ameliorate oncogenic potential in osteosarcomas. (PMID:32692461)
  • Association of polymorphisms in ADAMTS-7 gene with the susceptibility to coronary artery disease - a systematic review and meta-analysis. (PMID:33122452)
  • Coronary Disease Association With ADAMTS7 Is Due to Protease Activity. (PMID:34176299)
  • Genome-wide pleiotropy analysis of coronary artery disease and pneumonia identifies shared immune pathways. (PMID:35452290)
  • miR-654-5p Suppresses Migration and Proliferation of Vascular Smooth Muscle Cells by Targeting ADAMTS-7. (PMID:35462367)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_rerioadamts7ENSDARG00000102478
mus_musculusAdamts7ENSMUSG00000032363
rattus_norvegicusAdamts7ENSRNOG00000028036

Paralogs (25): ADAMTS6 (ENSG00000049192), ADAMTS2 (ENSG00000087116), PAPLN (ENSG00000100767), ADAMTS8 (ENSG00000134917), ADAMTS14 (ENSG00000138316), ADAMTS17 (ENSG00000140470), ADAMTS18 (ENSG00000140873), ADAMTS10 (ENSG00000142303), ADAMTSL4 (ENSG00000143382), ADAMTS16 (ENSG00000145536), ADAMTS19 (ENSG00000145808), ADAMTS12 (ENSG00000151388), ADAMTS1 (ENSG00000154734), ADAMTS5 (ENSG00000154736), ADAMTS3 (ENSG00000156140), ADAMTSL3 (ENSG00000156218), ADAMTS4 (ENSG00000158859), ADAMTS13 (ENSG00000160323), ADAMTS9 (ENSG00000163638), ADAMTS15 (ENSG00000166106), ADAMTS20 (ENSG00000173157), ADAMTSL1 (ENSG00000178031), ADAMTSL5 (ENSG00000185761), THSD4 (ENSG00000187720), ADAMTSL2 (ENSG00000197859)

Protein

Protein identifiers

A disintegrin and metalloproteinase with thrombospondin motifs 7 — Q9UKP4 (reviewed: Q9UKP4)

All UniProt accessions (1): Q9UKP4

UniProt curated annotations — full annotation on UniProt →

Function. Metalloprotease. Was previously shown to degrade COMP. However, a later study found no activity against COMP.

Subunit / interactions. Interacts with COMP.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Expressed in heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. Detected in meniscus, bone, tendon, cartilage, synovium, fat and ligaments.

Post-translational modifications. N-glycosylated. Can be O-fucosylated by POFUT2 on a serine or a threonine residue found within the consensus sequence C1-X(2)-(S/T)-C2-G of the TSP type-1 repeat domains where C1 and C2 are the first and second cysteine residue of the repeat, respectively. Fucosylated repeats can then be further glycosylated by the addition of a beta-1,3-glucose residue by the glucosyltransferase, B3GALTL. Fucosylation mediates the efficient secretion of ADAMTS family members. Can also be C-glycosylated with one or two mannose molecules on tryptophan residues within the consensus sequence W-X-X-W of the TPRs. N- and C-glycosylations can also facilitate secretion. O-glycosylated proteoglycan; contains chondroitin sulfate. May be cleaved by a furin endopeptidase. The precursor is sequentially processed.

Cofactor. Binds 1 zinc ion per subunit.

Domain organisation. The spacer domain and the TSP type-1 domains are important for a tight interaction with the extracellular matrix. The conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.

Induction. Up-regulated in articular cartilage and synovium from arthritis patients.

RefSeq proteins (1): NP_055087* (*=MANE)

Domains & families (InterPro)

IDNameType
IPR000884TSP1_rptRepeat
IPR001590Peptidase_M12BDomain
IPR002870Peptidase_M12B_NDomain
IPR010294ADAMTS_spacer1Domain
IPR010909PLACDomain
IPR013273ADAMTS/ADAMTS-likeFamily
IPR024079MetalloPept_cat_dom_sfHomologous_superfamily
IPR036383TSP1_rpt_sfHomologous_superfamily
IPR041645ADAMTS_CR_2Domain
IPR045371ADAMTS_CR_3Domain
IPR050439ADAMTS_ADAMTS-likeFamily

Pfam: PF00090, PF01421, PF01562, PF05986, PF17771, PF19030, PF19236

UniProt features (52 total): domain 11, disulfide bond 11, region of interest 5, sequence variant 5, sequence conflict 5, binding site 4, compositionally biased region 3, glycosylation site 3, signal peptide 1, propeptide 1, short sequence motif 1, chain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q9UKP4-F164.260.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 389

Ligand- & substrate-binding residues (4): 204 (in inhibited form); 388; 392; 398

Disulfide bonds (11): 318–372, 347–354, 366–447, 405–431, 474–497, 485–503, 492–522, 516–527, 550–587, 554–592, 565–577

Glycosylation sites (3): 94, 693, 778

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

IDPathway
R-HSA-5083635Defective B3GALTL causes PpS
R-HSA-5173214O-glycosylation of TSR domain-containing proteins
R-HSA-1643685Disease
R-HSA-3781865Diseases of glycosylation
R-HSA-3906995Diseases associated with O-glycosylation of proteins
R-HSA-392499Metabolism of proteins
R-HSA-5173105O-linked glycosylation
R-HSA-5668914Diseases of metabolism
R-HSA-597592Post-translational protein modification

MSigDB gene sets: 106 (showing top): GOBP_COLLAGEN_FIBRIL_ORGANIZATION, GOBP_CARTILAGE_DEVELOPMENT, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOMF_METALLOPEPTIDASE_ACTIVITY, GOBP_REGULATION_OF_CARTILAGE_DEVELOPMENT, GOBP_RESPONSE_TO_PEPTIDE, SP3_Q3, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOCC_CELL_SURFACE, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, TERAMOTO_OPN_TARGETS_CLUSTER_6, GOBP_ANATOMICAL_STRUCTURE_MATURATION, GOBP_BONE_DEVELOPMENT

GO Biological Process (12): chondrocyte differentiation (GO:0002062), proteoglycan metabolic process (GO:0006029), proteolysis (GO:0006508), extracellular matrix organization (GO:0030198), collagen fibril organization (GO:0030199), negative regulation of chondrocyte differentiation (GO:0032331), ossification involved in bone maturation (GO:0043931), obsolete proteolysis involved in protein catabolic process (GO:0051603), cellular response to interleukin-1 (GO:0071347), cellular response to tumor necrosis factor (GO:0071356), cellular response to BMP stimulus (GO:0071773), ossification (GO:0001503)

GO Molecular Function (6): metalloendopeptidase activity (GO:0004222), metallopeptidase activity (GO:0008237), metal ion binding (GO:0046872), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (4): endoplasmic reticulum lumen (GO:0005788), cell surface (GO:0009986), extracellular matrix (GO:0031012), extracellular region (GO:0005576)

Reactome top-level categories

Rollup of top-7 pathways:

CategoryPathways
Diseases associated with O-glycosylation of proteins1
O-linked glycosylation1
Diseases of metabolism1
Diseases of glycosylation1
Post-translational protein modification1
Disease1
Metabolism of proteins1

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular response to cytokine stimulus2
cellular anatomical structure2
cell differentiation1
cartilage development1
glycoprotein metabolic process1
protein metabolic process1
extracellular structure organization1
external encapsulating structure organization1
extracellular matrix organization1
chondrocyte differentiation1
regulation of chondrocyte differentiation1
negative regulation of cell differentiation1
negative regulation of cartilage development1
ossification1
bone maturation1
response to interleukin-11
response to tumor necrosis factor1
cellular response to growth factor stimulus1
response to BMP1
multicellular organismal process1
endopeptidase activity1
metallopeptidase activity1
peptidase activity1
cation binding1
binding1
hydrolase activity1
catalytic activity, acting on a protein1
catalytic activity1
endoplasmic reticulum1
intracellular organelle lumen1
external encapsulating structure1

Protein interactions and networks

STRING

906 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
ADAMTS7COMPP49747912
ADAMTS7FURINP09958744
ADAMTS7PHACTR1Q9C0D0702
ADAMTS7GRNP23781691
ADAMTS7A2MP01023545
ADAMTS7COL4A2P08572528
ADAMTS7MMP9P14780521
ADAMTS7PTHLHP12272521
ADAMTS7HHIPL1Q96JK4515
ADAMTS7ZC3HC1Q86WB0507
ADAMTS7JCADQ9P266507
ADAMTS7ADAMTS12P58397495
ADAMTS7MMP2P08253482
ADAMTS7ACANP16112481
ADAMTS7SORT1Q99523446

IntAct

59 interactions, top by confidence:

ABTypeScore
CRIPTOAIPpsi-mi:“MI:0914”(association)0.640
FBXO6MAN2B1psi-mi:“MI:0914”(association)0.640
FBXO2TMEM131Lpsi-mi:“MI:0914”(association)0.530
CTSGMANBApsi-mi:“MI:0914”(association)0.530
CMA1MANBApsi-mi:“MI:0914”(association)0.530
TIMP3ZZEF1psi-mi:“MI:0914”(association)0.530
A2MADAMTS7psi-mi:“MI:0570”(protein cleavage)0.440
ADAMTS7COMPpsi-mi:“MI:0570”(protein cleavage)0.440
HTRA1ADAMTS7psi-mi:“MI:0915”(physical association)0.370
CompADAMTS7psi-mi:“MI:0915”(physical association)0.370
SCGB2A2RTL8Cpsi-mi:“MI:0914”(association)0.350
GPIHBP1SAC3D1psi-mi:“MI:0914”(association)0.350
IGFL3CBX4psi-mi:“MI:0914”(association)0.350
DEFB136MANBApsi-mi:“MI:0914”(association)0.350
VEGFDRPSA2psi-mi:“MI:0914”(association)0.350
LY86TMEM131Lpsi-mi:“MI:0914”(association)0.350
IL5RAPOTEFpsi-mi:“MI:0914”(association)0.350
NCR3POTEFpsi-mi:“MI:0914”(association)0.350
LYPD4POTEFpsi-mi:“MI:0914”(association)0.350
CFC1POTEFpsi-mi:“MI:0914”(association)0.350
EDN3POTEFpsi-mi:“MI:0914”(association)0.350
PI15psi-mi:“MI:0914”(association)0.350
MFAP4QSOX1psi-mi:“MI:0914”(association)0.350
CA6QSOX1psi-mi:“MI:0914”(association)0.350
ELSPBP1QSOX1psi-mi:“MI:0914”(association)0.350
PRG2QSOX1psi-mi:“MI:0914”(association)0.350
DNASE1L1QSOX1psi-mi:“MI:0914”(association)0.350
INHBEMANBApsi-mi:“MI:0914”(association)0.350
PRTN3MANBApsi-mi:“MI:0914”(association)0.350

BioGRID (56): ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS), ADAMTS7 (Affinity Capture-MS)

ESM2 similar proteins: A1A5Y0, A1KZ92, A2AJ76, B0S5N4, D3YXG0, D3ZPX4, F1MMS9, O00187, O55005, O60500, O75093, O88279, O88280, P11627, P17852, P26006, P32004, P51805, P57110, P59511, P70208, P85171, Q05695, Q0PMG2, Q13219, Q3UH53, Q4KMG0, Q62470, Q62918, Q7Z5N4, Q80TR4, Q8AV58, Q8AXZ4, Q8CIY2, Q8HZK2, Q8HZK3, Q8NDA2, Q8R4K8, Q8TE57, Q91WP0

Diamond homologs: A2VEC9, B3EWY9, B3EWZ3, B3EWZ8, C0HL12, C5IAW9, D3YXF5, D3YXG0, D3Z7H8, D3ZTD8, E9Q6D8, F1LW30, G1FC92, G5ECS8, O08721, O08722, O08747, O14514, O15072, O60241, O60242, O95185, O95450, P07358, P07996, P10643, P11680, P13671, P27918, P35440, P35441, P35442, P35448, P48960, P55314, P57110, P58397, P59384, P61134, P61135

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 85 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

PathwayPartnersFoldFDR
Degradation of the extracellular matrix816.8×6e-06
Post-translational modification: synthesis of GPI-anchored proteins515.0×2e-03
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)69.3×3e-03
Extracellular matrix organization89.0×4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

402 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance319
Likely benign40
Benign9

Top pathogenic / likely-pathogenic (0)

SpliceAI

5192 predictions. Top by Δscore:

VariantEffectΔscore
15:78762563:GCA:Gacceptor_gain1.0000
15:78762564:CA:Cacceptor_gain1.0000
15:78762564:CAC:Cacceptor_gain1.0000
15:78762566:C:CCacceptor_gain1.0000
15:78768257:CAC:Cacceptor_gain1.0000
15:78773085:AGGC:Adonor_gain1.0000
15:78773097:T:TAdonor_gain1.0000
15:78773115:A:ACdonor_gain1.0000
15:78773116:C:CCdonor_gain1.0000
15:78773199:ACGTT:Aacceptor_gain1.0000
15:78773200:CGTT:Cacceptor_gain1.0000
15:78773200:CGTTC:Cacceptor_gain1.0000
15:78773202:TT:Tacceptor_gain1.0000
15:78773203:TC:Tacceptor_loss1.0000
15:78773204:C:CCacceptor_gain1.0000
15:78773204:C:Tacceptor_loss1.0000
15:78774151:T:TAdonor_gain1.0000
15:78774165:A:ATdonor_loss1.0000
15:78774166:C:CTdonor_loss1.0000
15:78774170:A:ACdonor_gain1.0000
15:78774171:C:CCdonor_gain1.0000
15:78774297:TTCA:Tacceptor_gain1.0000
15:78774298:TCA:Tacceptor_gain1.0000
15:78774299:CA:Cacceptor_gain1.0000
15:78774299:CAC:Cacceptor_gain1.0000
15:78774299:CACT:Cacceptor_loss1.0000
15:78774301:C:CCacceptor_gain1.0000
15:78774302:T:Aacceptor_loss1.0000
15:78774310:C:CTacceptor_gain1.0000
15:78774310:C:Tacceptor_gain1.0000

AlphaMissense

10925 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
15:78776818:G:CC497W0.999
15:78776819:C:GC497S0.999
15:78776820:A:TC497S0.999
15:78776821:C:AW496C0.999
15:78776821:C:GW496C0.999
15:78777490:C:GC474S0.999
15:78777491:A:TC474S0.999
15:78788269:C:AW428C0.999
15:78788269:C:GW428C0.999
15:78788271:A:GW428R0.999
15:78788271:A:TW428R0.999
15:78763932:C:AW1529C0.998
15:78763932:C:GW1529C0.998
15:78771753:G:CF736L0.998
15:78771753:G:TF736L0.998
15:78771755:A:GF736L0.998
15:78771756:G:CN735K0.998
15:78771756:G:TN735K0.998
15:78774643:C:AW619C0.998
15:78774643:C:GW619C0.998
15:78776329:C:GC522S0.998
15:78776330:A:TC522S0.998
15:78776820:A:GC497R0.998
15:78777489:G:CC474W0.998
15:78777490:C:AC474F0.998
15:78777491:A:GC474R0.998
15:78788257:G:CS432R0.998
15:78788257:G:TS432R0.998
15:78788259:T:GS432R0.998
15:78789751:G:CC372W0.998

dbSNP variants (sampled 300 via entrez): RS1000008302 (15:78799052 C>A), RS1000179486 (15:78758934 C>T), RS1000282700 (15:78768265 G>A), RS1000411137 (15:78807100 G>A), RS1000446333 (15:78798714 G>A), RS1000691907 (15:78787599 G>A), RS1001032532 (15:78773940 G>A), RS1001067907 (15:78811425 A>G), RS1001185856 (15:78778798 G>C,T), RS1001438428 (15:78811614 C>G,T), RS1001453031 (15:78769836 A>G), RS1001531099 (15:78807001 A>G,T), RS1001789361 (15:78794181 G>C), RS1001863400 (15:78808138 G>A), RS1001961930 (15:78806764 G>A)

Disease associations

OMIM: gene MIM:605009 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

83 associations (top):

StudyTraitp-value
GCST000945_1Coronary artery disease5.000000e-13
GCST000998_21Coronary heart disease1.000000e-12
GCST000999_1Coronary heart disease4.000000e-09
GCST001902_1Coronary artery calcification7.000000e-06
GCST002287_9Coronary artery disease or ischemic stroke2.000000e-09
GCST002289_17Coronary artery disease7.000000e-08
GCST002290_16Coronary artery disease or large artery stroke2.000000e-08
GCST003116_16Coronary artery disease4.000000e-16
GCST003117_31Myocardial infarction3.000000e-09
GCST003262_1010Post bronchodilator FEV18.000000e-07
GCST003262_1025Post bronchodilator FEV17.000000e-07
GCST003262_1027Post bronchodilator FEV11.000000e-06
GCST003262_1116Post bronchodilator FEV14.000000e-06
GCST003262_1117Post bronchodilator FEV15.000000e-06
GCST003262_1126Post bronchodilator FEV12.000000e-06
GCST003262_157Post bronchodilator FEV17.000000e-07
GCST003262_37Post bronchodilator FEV13.000000e-06
GCST003262_65Post bronchodilator FEV13.000000e-06
GCST003262_670Post bronchodilator FEV13.000000e-06
GCST003262_782Post bronchodilator FEV17.000000e-08
GCST003262_787Post bronchodilator FEV12.000000e-07
GCST003262_802Post bronchodilator FEV11.000000e-06
GCST003262_831Post bronchodilator FEV12.000000e-07
GCST003262_954Post bronchodilator FEV12.000000e-06
GCST003262_955Post bronchodilator FEV12.000000e-06
GCST003264_1119Post bronchodilator FEV1/FVC ratio5.000000e-07
GCST003264_1124Post bronchodilator FEV1/FVC ratio9.000000e-07
GCST003264_1183Post bronchodilator FEV1/FVC ratio1.000000e-06
GCST003264_1240Post bronchodilator FEV1/FVC ratio4.000000e-07
GCST003264_1241Post bronchodilator FEV1/FVC ratio5.000000e-07

EFO canonical traits (8, from GWAS)

EFO IDTrait name
EFO:0004723coronary artery calcification
EFO:0004314forced expiratory volume
EFO:0004713FEV/FVC ratio
EFO:0006336diastolic blood pressure
EFO:0004318smoking behavior
EFO:0004340body mass index
EFO:0005763pulse pressure measurement
EFO:0009369diffusing capacity of the lung for carbon monoxide

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724789 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — M12: Astacin/Adamalysin

Most potent curated ligand interactions (1 total), top 1:

LigandActionAffinityParameter
BAY-9835Inhibition8.24pIC50

Binding affinities (BindingDB)

241 measured of 269 human assays (269 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

LigandMeasureValuePatent
Ent-4’,5-Dichloro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC50463 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-4’-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC50510 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4-Fluoro-4’-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC50705 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC50728 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-4-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC50830 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC501020 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC501150 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
4’-(2,2-Difluorocyclopropyl)-5-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[1,1’-Biphenyl]-2-Carboxamide (Mixture of Diastereoisomers)IC501300 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-6-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC501300 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’,6-Dimethyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazoidin-4-Yl]Methyl}[1,1’-Biphenyl]-2-CarboxamideIC501400 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’,5-Dichloro-N-{[4-(1-Methyl-1H-Pyrazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC501570 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-6-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[1,1’-Biphenyl]-2-CarboxamideIC501600 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Fluoro-4’-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC501700 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-[[4-(1-methylimidazol-2-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamideIC501840 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC501850 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Methyl-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC501900 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Methyl-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC501900 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-N-[(4-Cyclobutyl-2,5-Dioxoimidazolidin-4-Yl)Methyl]-5-Methyl-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC502000 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-N-{[4-(1,5-Dimethyl-1H-Pyrazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC502100 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
4’-(2,2-Difluorocyclopropyl)-4-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[1,1’-Biphenyl]-2-Carboxamide (Mixture of Diastereoisomers)IC502100 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
4’-Cyclobutyl-N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC502200 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-4-Fluoro-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC502600 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-N-{[4-(5-Cyclopropyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC502700 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-N-{[4-(1-Methyl-1H-Pyrazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC502730 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-5,6-Dimethyl-4’-(Trifluoromethyl)[1,1’-Biphenyl]-2-CarboxamideIC502800 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4-Fluoro-4-Methyl[Biphenyl]-2-CarboxamideIC502800 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-5-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC503000 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
3-Chloro-N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-Methyl[1,1’-Biphenyl]-2-CarboxamideIC503000 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-2-[6-(Trifluoromethyl)Pyridin-3-Yl]BenzamideIC503050 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC503100 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’,6-Dimethyl[Biphenyl]-2-CarboxamideIC503200 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4-Fluoro-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503250 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
5-Chloro-N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-6-Fluoro-4’-(Trifluoromethyl)[1,1’-Biphenyl]-2-CarboxamideIC503400 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503500 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
5-Chloro-N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-Methyl[Biphenyl]-2-CarboxamideIC503500 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-4-Fluoro-N-{[4-(1-Methyl-1H-Pyrazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC503550 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
4’-(2,2-Difluorocyclopropyl)-5-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[1,1’-Biphenyl]-2-Carboxamide (Mixture of Diastereoisomers)IC503600 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-3,4’-Dichloro-N-{[4-(1-Methyl-1H-Pyrazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC503650 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Chloro-N-{[4-(4-Methyl-1,3-Thiazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503700 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
4’,5-Dichloro-N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}[1,1’-Biphenyl]-2-CarboxamideIC503700 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-3-Fluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503750 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Methyl-N-{[4-(4-Methyl-1,3-Thiazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503800 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-N-{[4-(5-Cyclopropyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-2-[6-(Trifluoromethyl)Pyridin-3-Yl]BenzamideIC503800 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’,5-Dimethyl[Biphenyl]-2-CarboxamideIC503900 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4,5-Difluoro-N-{[4-(1-Methyl-1H-Imidazol-2-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC503950 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
N-{[(4R)-4-Cyclopropyl-2,5-Dioxoimidazolidin-4-Yl]Methyl}-5-Methyl-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC504000 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-4’-Chloro-N-{[4-(1-Methyl-1H-Pyrazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}[Biphenyl]-2-CarboxamideIC504030 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-5-Fluoro-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC504130 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Ent-N-{[4-(2,4-Dimethyl-1,3-Thiazol-5-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC504150 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists
Rac-5-Methyl-N-{[4-(5-Methyl-1,3-Thiazol-4-Yl)-2,5-Dioxoimidazolidin-4-Yl]Methyl}-4’-(Trifluoromethyl)[Biphenyl]-2-CarboxamideIC504400 nMUS-12398120: Substituted hydantoinamides as ADAMTS7 antagonists

ChEMBL bioactivities

51 potent at pChembl≥5 of 52 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChemblTypeValueUnitMolecule
8.52IC503nMCHEMBL5571635
8.52IC503nMCHEMBL5574355
8.30IC505nMCHEMBL5595087
8.22IC506nMCHEMBL5567356
8.22Ki6nMCHEMBL5592306
8.22IC506nMCHEMBL5575976
8.10IC508nMCHEMBL5572837
8.05IC509nMCHEMBL5589887
8.05Ki9nMCHEMBL5589804
8.00IC5010nMCHEMBL5590012
7.89IC5013nMCHEMBL5082898
7.85IC5014nMCHEMBL5574922
7.82IC5015nMCHEMBL5592187
7.80IC5016nMCHEMBL5563780
7.75IC5018nMCHEMBL5568936
7.72IC5019nMCHEMBL5595652
7.72IC5019nMCHEMBL5592274
7.68IC5021nMCHEMBL5086874
7.58IC5026nMCHEMBL5092149
7.58IC5026nMCHEMBL5077651
7.54IC5029nMCHEMBL5562698
7.40Ki40nMCHEMBL5591230
7.40Ki40nMCHEMBL5594880
7.34IC5046nMCHEMBL5591976
7.33IC5047nMCHEMBL5085716
7.33IC5047nMCHEMBL5570826
7.30Ki50nMCHEMBL5595366
7.30Ki50nMCHEMBL5593273
7.30IC5050nMCHEMBL5589804
7.22IC5060nMCHEMBL5569538
7.22IC5060nMCHEMBL5589804
7.21IC5061nMCHEMBL5085514
7.16Ki70nMCHEMBL5593176
7.14IC5072nMCHEMBL5572305
7.10IC5079nMCHEMBL5569748
7.00IC5099nMCHEMBL5567489
6.94IC50115nMCHEMBL5086082
6.89IC50129nMCHEMBL5076179
6.75IC50180nMCHEMBL5073508
6.66Ki220nMCHEMBL5594088
6.64IC50230nMCHEMBL5082246
6.55IC50280nMCHEMBL5593541
6.42Ki380nMCHEMBL5589746
6.26Ki550nMCHEMBL5592123
6.24IC50580nMCHEMBL5572058
6.07IC50850nMCHEMBL5570775
6.04IC50910nMCHEMBL5590568
6.03IC50930nMCHEMBL5574157
6.03Ki940nMCHEMBL5590061
6.00Ki1000nMCHEMBL5593591

PubChem BioAssay actives

50 with measured affinity, of 54 total; 48 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

CompoundAssayTypeValueUnit
N-[[4-(1-methylimidazol-2-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0030uM
4-chloro-3-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0030uM
3-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0050uM
N-[[4-(5-methyl-1,3-thiazol-4-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0060uM
(2R)-2-(1-benzoylpiperidin-4-yl)-2-[[4-(4-fluorophenyl)phenyl]sulfonylamino]-N-hydroxyacetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0060uM
3,4-difluoro-N-[[4-(4-methyl-1-phenylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0080uM
(2R)-2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-[[4-[4-(trifluoromethyl)phenyl]phenyl]sulfonylamino]acetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0090uM
3,4-difluoro-N-[[4-(5-methyl-2-pyridin-3-yl-1,3-thiazol-4-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0090uM
3-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-4-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0100uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(3-fluorophenyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0130uM
N-[[2,5-dioxo-4-(1,3-thiazol-4-yl)imidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0140uM
N-[[4-(2,5-dimethyl-1,3-thiazol-4-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0150uM
3-chloro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0160uM
N-[[4-(2-ethylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0180uM
4-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0190uM
5-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0190uM
2-(3-chlorophenyl)-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0210uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(4-fluorophenyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0260uM
2-(4-chlorophenyl)-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0260uM
3-methoxy-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0290uM
(2R)-2-(1-benzoylpiperidin-4-yl)-2-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonylamino]-N-hydroxyacetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0400uM
(2R)-2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-[[4-(4-methoxyphenyl)phenyl]sulfonylamino]acetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0400uM
N-[[4-(1,5-dimethylpyrazol-4-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0460uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(4-methylphenyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0470uM
3,4-difluoro-N-[[4-(5-methyl-2-phenyl-1,3-thiazol-4-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0470uM
N-[4-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonylamino]-5-(hydroxyamino)-3-methyl-5-oxopentyl]benzamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0500uM
(2R)-2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-[methyl-[4-[4-(trifluoromethyl)phenyl]phenyl]sulfonylamino]acetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0500uM
N-[[2,5-dioxo-4-[2-(2,2,2-trifluoroethyl)pyrazol-3-yl]imidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0600uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-phenyltriazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0610uM
N-[(4R)-4-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonylamino]-5-(hydroxyamino)-5-oxopentyl]benzamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.0700uM
N-[[2,5-dioxo-4-[5-(trifluoromethyl)-1,3-thiazol-4-yl]imidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0720uM
2-fluoro-N-[[(4S)-4-(2-methylpyrazol-3-yl)-2,5-dioxoimidazolidin-4-yl]methyl]-6-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0790uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-[4-(trifluoromethyl)phenyl]benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.0990uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(5-fluoro-2-pyridinyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.1150uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-1-phenylpyrazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.1290uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(2-fluorophenyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.1800uM
(2R)-3-(1-benzoylpiperidin-4-yl)-2-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonylamino]-N-hydroxypropanamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.2200uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(1,2-thiazol-4-yl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.2300uM
1-[(4-chlorophenyl)methyl]-N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]pyrazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.2800uM
1-benzoyl-4-[[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonylamino]-N-hydroxypiperidine-4-carboxamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.3800uM
(2R)-2-(1-benzoylpiperidin-4-yl)-2-[[4-[4-(dimethylamino)phenyl]phenyl]sulfonylamino]-N-hydroxyacetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.5500uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-4-(4-methylphenyl)benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.5800uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-[(1-methylpyrazol-4-yl)methyl]triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.8500uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-(1,3-thiazol-2-ylmethyl)triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.9100uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-2-[(2-methyl-1,3-thiazol-4-yl)methyl]triazole-4-carboxamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic500.9300uM
(2R)-2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-[[4-(4-morpholin-4-ylphenyl)phenyl]sulfonylamino]acetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki0.9400uM
(2R)-2-(1-benzoylpiperidin-4-yl)-N-hydroxy-2-[[4-[3-(trifluoromethyl)phenyl]phenyl]sulfonylamino]acetamide2114991: Inhibition of recombinant human full-length ADAMTS7 truncated before the C-terminal PLAC domain using FAM-Glu-Ala-Ala-Ala-Arg-Ala-Glu-Ala-Ala-Ala-Lys-TAMRA as substrate measured after 24 hrs by FRET assayki1.0000uM
N-[[(4R)-4-cyclopropyl-2,5-dioxoimidazolidin-4-yl]methyl]-3-(4-methylphenyl)benzamide2089697: Inhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayic502.3000uM

CTD chemical–gene interactions

25 total (human), top 25 by PubMed support.

ChemicalActions (top 5)PubMed papers
Particulate Matterdecreases expression, increases abundance, affects expression3
Cisplatinaffects cotreatment, increases expression, decreases expression2
Doxorubicinincreases expression2
sodium arsenitedecreases expression1
3,4,5,3’,4’-pentachlorobiphenylincreases expression1
CGP 52608affects binding, increases reaction1
nutlin 3affects cotreatment, increases expression1
abrinedecreases expression1
jinfukangaffects cotreatment, increases expression1
Resveratrolaffects cotreatment, decreases expression1
Sunitinibdecreases expression1
Air Pollutantsdecreases expression, increases abundance1
Benzo(a)pyreneincreases expression1
Camptothecinincreases expression1
Dactinomycinaffects cotreatment, increases expression1
Estradiolaffects cotreatment, increases expression1
Methotrexatedecreases expression1
Phthalic Acidsincreases methylation1
Plant Extractsaffects cotreatment, decreases expression1
Smokedecreases expression1
Tobacco Smoke Pollutionincreases expression1
Tretinoindecreases expression1
Paclitaxelaffects cotreatment, decreases expression1
Genisteinincreases expression1
Acrylamidedecreases expression1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay IDTypeDescriptionSource paper
CHEMBL5530428BindingInhibition of recombinant ADAMTS7 (unknown origin) using HiLyteFluor-488 DELSSMVLELRGLRT-K(QXL520)-E-NH2 as substrate incubated for 120 mins by FRET assayBAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.

  • Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): large artery stroke, stroke disorder

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 80

This page pulls from 80 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgtopdb_interactiongwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpatentpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomereactomeparentrefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot